Periodic Paralyses Workup

  • Author: Naganand Sripathi, MD; Chief Editor: Nicholas Lorenzo, MD   more...
 
Updated: Nov 25, 2010
 

Laboratory Studies

Hypokalemic periodic paralyses

Serum potassium level decreases during attacks but not necessarily below normal. Creatine phosphokinase (CPK) level rises during attacks. In a recent study, transtubular potassium concentration gradient (TTKG) and potassium-creatinine ratio (K/C) distinguished primary hypokalemic PP from secondary PP resulting from a large deficit of potassium. Values of more than 3.0 mmol/mmol (TTKG) and 2.5 mmol/mmol (PCR) indicated secondary hypokalemic PP.

A random urine potassium-creatinine ratio (K/C) of less than 1.5 is indicative of poor intake, gastrointestinal loss, and potassium shift into the cells. If hypokalemia is associated with paralysis, one should consider hyperthyroidism or familial or sporadic periodic paralysis.

Some of the medical conditions associated with hypokalemia are included in the table below (modified from Assadi 2008[7] ).

Table 5. Medical Conditions Associated With Hypokalemia (Open Table in a new window)

Urine K/C RatioAcid Base StatusOther Associated FeaturesMedical



Conditions



< 1.5Metabolic acidosisLower GI loss – Laxative abuse, diarrhea
< 1.5Metabolic alkalosisNormal BPSurreptitious vomiting
>1.5Metabolic acidosisDKA, type 1 or type 2 distal RTA
>1.5Metabolic alkalosisNormal BPDiuretic use, Bartter syndrome, Gitelman syndrome
≥1.5Metabolic alkalosisHypertensionPrimary aldosteronism, Cushing syndrome, renal artery stenosis, congenital adrenal hyperplasia, apparent mineralocorticoid excess, Liddle syndrome

ECG may show sinus bradycardia and evidence of hypokalemia (flattening of T waves, U waves in leads II, V 2 , V 3 , and V 4 , and ST-segment depression).

Hyperkalemic periodic paralyses

Serum potassium level may increase to as high as 5-6 mEq/L. Sometimes, it may be at the upper limit of normal, and it seldom reaches cardiotoxic levels. Serum sodium level may fall as potassium level rises. This results from sodium entry into the muscle. Water also moves in this direction, causing hemoconcentration and further hyperkalemia. Hyperregulation may occur at the end of an attack, causing hypokalemia. Water diuresis, creatinuria, and an increase in CPK level also may occur at the end of an attack.

ECG may show tall T waves.

Table 6. Diagnostic Studies of Hypokalemic and Hyperkalemic Periodic Paralyses (Open Table in a new window)

Hypokalemic PPHyperkalemic PP
Serum potassiumMildly depressed; may reach 1-5 mEq/LIncreases from baseline but may not increase beyond normal range
Serum CPKModerately elevated during attacksMildly elevated during attacks
ECGBradycardia



Flat T waves, U waves, ST-segment depression



Tall T waves
Next

Other Tests

Electrodiagnosis and provocative testing can be performed for periodic paralysis.

Previous
Next

Electrodiagnosis

Nerve conduction studies

  • The compound muscle action potential (CMAP) amplitude declines during the paralytic attack, more so in hypokalemic periodic paralysis. Sensory nerve conduction study findings are normal in most patients with periodic paralyses. Nerve conduction findings may be abnormal when the patient has peripheral neuropathy associated with thyrotoxicosis.
  • Repetitive nerve stimulation in hyperkalemic periodic paralysis may show a decrement in CMAP (accentuated by cooling) that is steadily progressive without tendency to recover as in myasthenia gravis. The amount of decrement is variable and increases with increased frequency of stimulation. In some patients, it is seen only with stimulation greater than 25 Hz.[8]

Muscle cooling

  • Cooling of muscle to 20°C leads to force reduction and prolonged twitch-relaxation in PC and hyperkalemic periodic paralyses. Muscle paralysis is prolonged and persistent even after rewarming.
  • As the muscle depolarizes at different temperatures in different patients, a muscle temperature of 20-25°C is preferable. This is best achieved by immersing the whole arm in ice water. This alone causes weakness in many patients.
  • Short periods of exercise (2-3 1-second short exercises) enhance the weakness and result in a very small CMAP.[8]

Exercise test in periodic paralyses

  • This is one of the most informative diagnostic tests for periodic paralyses. The test is based on 2 previously described observations: that CMAP amplitude is low in the muscle weakened by periodic paralyses and the weakness can be induced by exercise. Recording electrodes are placed over the hypothenar muscle and a CMAP is obtained by giving supramaximal stimuli. The stimuli are repeated every 30-60 seconds for a period of 2-3 minutes, until a stable baseline amplitude is obtained. Two kinds of exercise tests can be performed.
  • A short exercise test is one in which the muscle is contracted strongly in isometric conditions for 10-12 seconds. CMAPs are obtained 2 seconds immediately after exercise an then every 10 seconds for 50 seconds. In hyperkalemic periodic paralyses patients carrying T704M mutations, increase in CMAP amplitude (approximately 23%) occurs. In HypoPP1 and HypoPP2 patients, the increase is not significantly different from the control subjects (about 5%).
  • In the long exercise test, the muscle is contracted for 5 minutes, with brief (3- to 4-second) rests every 15 seconds to prevent muscle ischemia. The CMAP is recorded every minute during exercise and every 1-2 minutes after exercise for a period of 30 minutes or until no further decrement is observed in the amplitude of CMAP. Percentage of decrement is calculated by subtracting the smallest amplitude after exercise from the greatest amplitude after exercise and dividing it by the greatest amplitude after exercise. After a brief increase in CMAP amplitude, a decrease of more than 40% in the CMAP amplitude after 20 minutes is considered abnormal. An abnormal result is highly suggestive of periodic paralyses (98% specificity) but does not distinguish between hyperkalemic, hypokalemic, and thyrotoxic periodic paralyses. Different electrophysiologic patterns are identified in different group of patients with distinct mutations by using both these tests.

Table 7. Electrophysiological Patterns to Exercise Testing (Open Table in a new window)

Para-



myotonia



Congenita



Hyper-



kalemic



Periodic Paralysis



Hypo-



kalemic



Periodic Paralysis



Electrophysiological



pattern



IIVV
Channel mutationsSodium T1313M, R1448CSodium T704MCalcium R528H
Short Exercise Test:
Post exercise myotonic potentialsYesNoNo
CMAP amplitude



change after First trial



Increase or



decrease



IncreaseNo
CMAP amplitude



change after second



and third trial



Gradual



increase



Gradual



increase



No
Long Exercise Test:
Immediate change of



CMAP amplitude



DecreaseIncreaseNo
Late change of CMAP amplitudeDecreaseDecreaseDecrease
Modified from Fournier et al, 2004.[9]

Needle electrode examination

  • Insertional activity: The presence of myotonia usually excludes the diagnosis of hypokalemic periodic paralyses. In hyperkalemic periodic paralyses, no abnormality is detectable between attacks. In those patients with both clinical and electrical myotonia, mild to moderate spontaneous activity is seen, consisting of fibrillation potentials, positive sharp waves, and myotonic discharges.
  • Myotonia: Electrical myotonia consists of repetitive discharges at rates of 20-80 Hz. The shape of the potentials can be either positive sharp waves or small biphasic waves; the former is seen while moving the needle electrode and the latter following muscle contraction. Another criterion distinct for myotonia is waxing and waning of the amplitude and frequency of the discharges (ie, dive-bomber discharges). These discharges should last a minimum of 500 milliseconds. They should be elicited in at least 3 areas outside the endplate region in order to distinguish minimal electromyographic myotonia from insertional activity. Demonstration of myotonia may be facilitated by potassium administration and cold temperature.
  • Motor unit action potential (MUAP): During the paralytic attack, recruitment is reduced, with few voluntary MUAPs. The amplitude and duration of MUAPs may be reduced. In patients who develop myopathy, the MUAPs tend to show decreased amplitude, reduced duration, and increased proportion of polyphasic potentials.
Previous
Next

Provocative Testing

General precautions for such testing include (1) physician presence during testing, (2) performance of testing in an intensive care setting, (3) avoidance of testing patients with serum potassium disturbances, diabetes mellitus, or renal or cardiac dysfunction, (4) close monitoring of ECG, and (5) capability for rapid electrolyte and glucose testing and correction.

  • Hypokalemic periodic paralyses: Provocative testing is dangerous and is not the first line of diagnostic testing.
    • Oral glucose loading test: Glucose is given orally at a dose of 1.5 g/kg to a maximum of 100 g over a period of 3 minutes with or without 10-20 units of subcutaneous insulin. Muscle strength is tested every 30 minutes. Full electrolyte profile is tested every 30 minutes for 3 hours and hourly for the next 2 hours. Weakness usually is detected within 2-3 hours, and if not patients should be considered for intravenous (IV) glucose challenge.
    • Intravenous glucose challenge: Good IV access is essential and availability of more than one IV line is preferred. Glucose is infused IV over a period of 1 hour at a dose of 3 g/kg to a maximum of 200 g (in water at 2 g/5 mL). If no weakness is detectable at 30 minutes, 0.1 U/kg of IV insulin is given. Insulin can be repeated in 60 minutes if weakness is not detected. Strength is evaluated every 15 minutes for 2 hours. Electrolytes, glucose, and carbon dioxide are measured every 30 minutes and once more after the patient becomes weak. ECG is repeated every 30 minutes. The most dangerous period of the testing is between 75-150 minutes when severe hypoglycemia occurs. This should be reversed immediately.
    • Intra-arterial epinephrine test: Two mcg/min of epinephrine is infused into the brachial artery for 5 minutes and the amplitude of the CMAP is recorded from a hand muscle. CMAPs are recorded before, during, and 30 minutes after infusion. The result is considered positive if a decrement of more than 30% occurs within 10 minutes of infusion.
  • Hyperkalemic periodic paralyses: Potassium chloride 0.05 g/kg in a sugar-free liquid is given orally over 3 minutes in a fasting state, just after exercise. If no weakness occurs, an additional amount of potassium chloride (0.10-0.15 g/kg) is given. Electrolyte profile, ECG, and strength are tested every 15 minutes for 2 hours and then every 30 minutes for the next 2 hours. Weakness usually is detected between 90-180 minutes after initiation of testing.
Previous
Next

Histologic Findings

Muscle biopsy is abnormal, more typically in patients with hypokalemic periodic paralysis (PP) than in patients with hyperkalemic periodic paralysis (PP). Histologic findings in hypokalemic PP include the following:

  • The most characteristic abnormality is the presence of vacuoles in the muscle fibers. Sometimes, they fill the muscle fibers, and in some patients, groups of vacuoles may be noted. These changes are more marked in hypokalemic PP than in hyperkalemic PP. In the latter, the vacuoles are small and peripherally located. Reports of muscle biopsy findings in PC are few and the vacuolar changes are less frequent.
  • Signs of myopathy include muscle fiber size variability, split fibers, and internal nuclei. Muscle fiber atrophy may be present in clinically affected muscles.
  • Tubular aggregates may be seen in some patients. Tubular aggregates are seen in type II fibers. They are subsarcolemmal in location. This abnormality is seen only in hypokalemic PP.
  • Muscle fiber necrosis is rare.
Previous
 
 
Contributor Information and Disclosures
Author

Naganand Sripathi, MD  Director, Neuromuscular Clinic, Department of Neurology, Henry Ford Hospital

Naganand Sripathi, MD is a member of the following medical societies: American Academy of Neurology, American Medical Association, Michigan State Medical Society, and New York Academy of Sciences

Disclosure: Nothing to disclose.

Specialty Editor Board

Paul E Barkhaus, MD  Professor, Department of Neurology, Medical College of Wisconsin; Director of Neuromuscular Diseases, Milwaukee Veterans Administration Medical Center

Paul E Barkhaus, MD is a member of the following medical societies: American Academy of Neurology, American Association of Neuromuscular and Electrodiagnostic Medicine, and American Neurological Association

Disclosure: Nothing to disclose.

Francisco Talavera, PharmD, PhD  Senior Pharmacy Editor, eMedicine

Disclosure: eMedicine Salary Employment

Glenn Lopate, MD  Associate Professor, Department of Neurology, Division of Neuromuscular Diseases, Washington University School of Medicine; Director of Neurology Clinic, St Louis ConnectCare; Consulting Staff, Department of Neurology, Barnes-Jewish Hospital

Glenn Lopate, MD is a member of the following medical societies: American Academy of Neurology, American Association of Neuromuscular and Electrodiagnostic Medicine, and Phi Beta Kappa

Disclosure: Nothing to disclose.

Selim R Benbadis, MD  Professor, Director of Comprehensive Epilepsy Program, Departments of Neurology and Neurosurgery, University of South Florida School of Medicine, Tampa General Hospital

Selim R Benbadis, MD is a member of the following medical societies: American Academy of Neurology, American Academy of Sleep Medicine, American Clinical Neurophysiology Society, American Epilepsy Society, and American Medical Association

Disclosure: UCB Pharma Honoraria Speaking, consulting; Lundbeck Honoraria Speaking, consulting; Cyberonics Honoraria Speaking, consulting; Glaxo Smith Kline Honoraria Speaking, consulting; Ortho McNeil Honoraria Speaking, consulting; Pfizer Honoraria Speaking, consulting; Sleepmed/DigiTrace Speaking, consulting

Chief Editor

Nicholas Lorenzo, MD  Chief Editor, eMedicine Neurology; Consulting Staff, Neurology Specialists and Consultants

Nicholas Lorenzo, MD is a member of the following medical societies: Alpha Omega Alpha and American Academy of Neurology

Disclosure: Nothing to disclose.

References
  1. Miller TM, Dias da Silva MR, Miller HA, et al. Correlating phenotype and genotype in the periodic paralyses. Neurology. Nov 9 2004;63(9):1647-55. [Medline].

  2. Venance SL, Cannon SC, Fialho D, et al. The primary periodic paralyses: diagnosis, pathogenesis and treatment. Brain. Jan 2006;129(Pt 1):8-17. [Medline].

  3. Matthews E, Labrum R, Sweeney MG, Sud R, Haworth A, Chinnery PF, et al. Voltage sensor charge loss accounts for most cases of hypokalemic periodic paralysis. Neurology. May 5 2009;72(18):1544-7. [Medline].

  4. Arzel-Hezode M, McGoey S, Sternberg D, Vicart S, Eymard B, Fontaine B. Glucocorticoids may trigger attacks in several types of periodic paralysis. Neuromuscul Disord. Mar 2009;19(3):217-9. [Medline].

  5. Donaldson MR, Yoon G, Fu YH, Ptacek LJ. Andersen-Tawil syndrome: a model of clinical variability, pleiotropy, and genetic heterogeneity. Ann Med. 2004;36 Suppl 1:92-7. [Medline].

  6. Dias Da Silva MR, Cerutti JM, Arnaldi LA, Maciel RM. A mutation in the KCNE3 potassium channel gene is associated with susceptibility to thyrotoxic hypokalemic periodic paralysis. J Clin Endocrinol Metab. Nov 2002;87(11):4881-4. [Medline].

  7. Assadi F. Diagnosis of hypokalemia: a problem-solving approach to clinical cases. Iran J Kidney Dis. Jul 2008;2(3):115-22. [Medline].

  8. Streib EW. AAEE minimonograph #27: Differential diagnosis of myotonic syndromes. Muscle Nerve. Sep 1987;10(7):603-15. [Medline].

  9. Fournier E, Arzel M, Sternberg D, et al. Electromyography guides toward subgroups of mutations in muscle channelopathies. Ann Neurol. Nov 2004;56(5):650-61. [Medline].

  10. Levitt JO. Practical aspects in the management of hypokalemic periodic paralysis. J Transl Med. Apr 21 2008;6:18. [Medline].

  11. Junker J, Haverkamp W, Schulze-Bahr E, Eckardt L, Paulus W, Kiefer R. Amiodarone and acetazolamide for the treatment of genetically confirmed severe Andersen syndrome. Neurology. Aug 13 2002;59(3):466. [Medline].

  12. Pellizzón OA, Kalaizich L, Ptácek LJ, Tristani-Firouzi M, Gonzalez MD. Flecainide suppresses bidirectional ventricular tachycardia and reverses tachycardia-induced cardiomyopathy in Andersen-Tawil syndrome. J Cardiovasc Electrophysiol. Jan 2008;19(1):95-7. [Medline].

  13. Elbaz A, Vale-Santos J, Jurkat-Rott K. Hypokalemic periodic paralysis and the dihydropyridine receptor (CACNL1A3): genotype/phenotype correlations for two predominant mutations and evidence for the absence of a founder effect in 16 caucasian families. Am J Hum Genet. Feb 1995;56(2):374-80. [Medline].

  14. Engel AG, Lambert EH, Rosevear JW, Tauxe WN. Clinical and electromyographic studies in a patient with primary hypokalemic periodic paralysis. Am J Med. Apr 1965;38:626-40. [Medline].

  15. Griggs RC. Evaluation and Treatment of Myopathies. 1995. Philadelphia: FA Davis; 318-354.

  16. Hoffman EP, Lehmann-Horn F, Rudel R. Overexcited or inactive: ion channels in muscle disease. Cell. Mar 10 1995;80(5):681-6. [Medline].

  17. Junker J, Haverkamp W, Schulze-Bahr E, et al. Amiodarone and acetazolamide for the treatment of genetically confirmed severe Andersen syndrome. Neurology. Aug 13 2002;59(3):466. [Medline].

  18. Koch MC, Steinmeyer K, Lorenz C. The skeletal muscle chloride channel in dominant and recessive human myotonia. Science. Aug 7 1992;257(5071):797-800. [Medline].

  19. Lin SH, Lin YF, Chen DT, et al. Laboratory tests to determine the cause of hypokalemia and paralysis. Arch Intern Med. Jul 26 2004;164(14):1561-6. [Medline].

  20. McManis PG, Lambert EH, Daube JR. The exercise test in periodic paralysis. Muscle Nerve. Oct 1986;9(8):704-10. [Medline].

  21. Meola G, Sansone V. Treatment in myotonia and periodic paralysis. Rev Neurol (Paris). May 2004;160(5 Pt 2):S55-69. [Medline].

  22. Platt D, Griggs R. Skeletal muscle channelopathies: new insights into the periodic paralyses and nondystrophic myotonias. Curr Opin Neurol. Oct 2009;22(5):524-31. [Medline]. [Full Text].

  23. Ptacek L. The familial periodic paralyses and nondystrophic myotonias. Am J Med. Jul 1998;105(1):58-70. [Medline].

  24. Ptacek LJ, Johnson KJ, Griggs RC. Genetics and physiology of the myotonic muscle disorders. N Engl J Med. Feb 18 1993;328(7):482-9. [Medline].

  25. Ruff RL. Slow inactivation: slow but not dull. Neurology. Mar 4 2008;70(10):746-7. [Medline].

  26. Tricarico D, Barbieri M, Mele A, et al. Carbonic anhydrase inhibitors are specific openers of skeletal muscle BK channelof K+-deficient rats. FASEB J. Apr 2004;18(6):760-1. [Medline].

  27. Zhang J, George AL, Griggs RC. Mutations in the human skeletal muscle chloride channel gene (CLCN1) associated with dominant and recessive myotonia congenita. Neurology. Oct 1996;47(4):993-8. [Medline].

Previous
Next
 
Table 1. Primary Periodic Paralysis
Sodium channelHyperkalemic PP (HyperPP)



Hypokalemic PP (HypoPP2)



Paramyotonia congenita



Calcium channelHypokalemic PP (HypoPP1)
Potassium channelAndersen-Tawil syndrome



Hyperkalemic PP or hypokalemic PP*



*The deficit was described in 2 small families and has not been substantiated by others.[1, 2]
Table 2. Distinguishing Features Among the Common Forms of Periodic Paralyses
SyndromeAge of OnsetDuration of AttackPrecipitating



Factors



Severity of AttacksAssociated



Features



Hyper-kalemic periodic paralysesFirst decade of lifeFew minutes to less than 2 h (mostly less than 1 h)Low carbohydrate intake (fasting)



Cold



Rest following exercise



Alcohol



Infection



Emotional stress



Trauma



Menstrual period



Rarely severePerioral and limb paresthesias



Myotonia frequent



Occasional pseudo-hypertrophy of muscles



Hypo-kalemic periodic paralysesVariable -Childhood to third decade



Majority of cases before 16 years



Few hours to almost a week



Typically no longer than 72 h



Early morning attacks after previous day physical activity



High-carbohydrate meal, Chinese food, alcohol



Cold, change in barometric pressure or humidity



Fever, upper respiratory tract infections



Lack of sleep,



fatigue



Menstrual cycle



Severe



Complete paralysis



Occasional myotonic lid lag



Myotonia between attacks rare



Unilateral, partial, monomelic



Fixed muscle weakness late in disease



Potassium- associated myotoniaFirst decadeNo weaknessCold



Rest after exercise



Attacks of stiffness can be mild to severeMuscle hypertrophy
Para-myotonia congenitaFirst decade2-24 hColdRarely severePseudo-hypertrophy of muscles



Paradoxical myotonia



Fixed weakness rare



Thyrotoxic periodic paralysesThird and fourth decadesFew hours to 7 dSame as hypokalemic PP



Hyper-insulinemia



Same as hypokalemic PPFixed muscle weakness may develop



Hypokalemia during attacks



Table 3. Differential Diagnosis of Secondary Periodic Paralyses
HypokalemicHyperkalemic
Urinary potassium-wasting syndromes
  • Hyperaldosteronism
  • Conn syndrome
  • Bartter syndrome
  • Licorice intoxication
AlcoholAddison disease



Chronic renal failure



Hyporeninemic



Hypoaldosteronism



Drugs - Amphotericin B, bariumIleostomy with tight stoma
Renal tubular acidosisPotassium load
GI potassium-wasting syndromes
  • Laxative abuse
  • Severe diarrhea
Potassium-sparing diuretics
Table 4. Differential Diagnosis of Other Entities Causing Acute Generalized Weakness
DisorderPattern and



Distribution of



Weakness



Transient ischemic attacksFollow CNS distribution (ie, hemiparetic)



May have sensory symptoms and signs



Sleep attacksOccur at onset or termination of sleep



Last only minutes



Myelopathy
  • Traumatic
  • Transverse myelitis
  • Ischemic
Sensory symptoms



Presence of a sensory level



Sphincter involvement



Myasthenia gravis



Lambert-Eaton myasthenic syndrome



Subacute in onset



Associated autonomic symptoms in LEMS



Hyporeflexia in LEMS



Abnormal repetitive nerve stimulation



Presence of distinct antibodies



Peripheral neuropathy of acute onset
  • Acute inflammatory
  • demyelinating poly-radiculoneuropathy
  • Porphyria
Pattern of weakness



Absent stretch reflexes



Toxins
  • Ciguatera
  • Tetrodotoxin
Clinical presentation
Table 5. Medical Conditions Associated With Hypokalemia
Urine K/C RatioAcid Base StatusOther Associated FeaturesMedical



Conditions



< 1.5Metabolic acidosisLower GI loss – Laxative abuse, diarrhea
< 1.5Metabolic alkalosisNormal BPSurreptitious vomiting
>1.5Metabolic acidosisDKA, type 1 or type 2 distal RTA
>1.5Metabolic alkalosisNormal BPDiuretic use, Bartter syndrome, Gitelman syndrome
≥1.5Metabolic alkalosisHypertensionPrimary aldosteronism, Cushing syndrome, renal artery stenosis, congenital adrenal hyperplasia, apparent mineralocorticoid excess, Liddle syndrome
Table 6. Diagnostic Studies of Hypokalemic and Hyperkalemic Periodic Paralyses
Hypokalemic PPHyperkalemic PP
Serum potassiumMildly depressed; may reach 1-5 mEq/LIncreases from baseline but may not increase beyond normal range
Serum CPKModerately elevated during attacksMildly elevated during attacks
ECGBradycardia



Flat T waves, U waves, ST-segment depression



Tall T waves
Table 7. Electrophysiological Patterns to Exercise Testing
Para-



myotonia



Congenita



Hyper-



kalemic



Periodic Paralysis



Hypo-



kalemic



Periodic Paralysis



Electrophysiological



pattern



IIVV
Channel mutationsSodium T1313M, R1448CSodium T704MCalcium R528H
Short Exercise Test:
Post exercise myotonic potentialsYesNoNo
CMAP amplitude



change after First trial



Increase or



decrease



IncreaseNo
CMAP amplitude



change after second



and third trial



Gradual



increase



Gradual



increase



No
Long Exercise Test:
Immediate change of



CMAP amplitude



DecreaseIncreaseNo
Late change of CMAP amplitudeDecreaseDecreaseDecrease
Modified from Fournier et al, 2004.[9]
Previous
Next
 
 
 
 
 
All material on this website is protected by copyright, Copyright © 1994-2012 by WebMD LLC.
This website also contains material copyrighted by 3rd parties.

DISCLAIMER: The content of this Website is not influenced by sponsors. The site is designed primarily for use by qualified physicians and other medical professionals. The information contained herein should NOT be used as a substitute for the advice of an appropriately qualified and licensed physician or other health care provider. The information provided here is for educational and informational purposes only. In no way should it be considered as offering medical advice. Please check with a physician if you suspect you are ill.